SpyGlass Pharma, Inc. (SGP) intrinsic value & 10-year financials
SpyGlass Pharma, Inc. (SGP) has no Graham intrinsic value right now because the formula needs positive earnings.
- Graham intrinsic value
- —
- Share price (Oct 17, 2026)
- $24.00
- Market cap
- $53.2M
- Revenue (FY2025)
- —
- ROIC (10-yr avg)
- 34.0%
- Free cash flow (FY2025)
- -$33.5M
SGP 10-year financial history
| Fiscal year | Revenue | Net income | EPS (diluted) | Free cash flow | Operating margin | ROIC |
|---|---|---|---|---|---|---|
| FY2025 | — | -$39.9M | -$17.98 | -$33.5M | — | 31.1% |
| FY2024 | — | -$29.2M | -$16.31 | -$24.0M | — | 36.9% |
| FY2023 | — | — | — | — | — | — |
Source: annual 10-K filings on SEC EDGAR. Figures in USD.
Executive summary
SpyGlass Pharma, Inc. revenue growth over the past decade is N/A; insufficient history prevents a reliable 10-year CAGR calculation.
SpyGlass Pharma, Inc. has earned high returns on invested capital, averaging 34.0% ROIC over the available history. High ROIC is consistent with a durable franchise, but it is not by itself proof of an economic moat.
SpyGlass Pharma, Inc. capital allocation metrics are N/A for the decade; share count and net debt history are incomplete.
Benjamin Graham lens
SpyGlass Pharma, Inc. is evaluated under Benjamin Graham's defensive framework using SEC EDGAR fundamentals using an 8.5 + 2g earnings multiple and a 5.1% AAA bond-yield baseline.